Mylan Claims Ranbaxy Sitting On Hypertension Drug Exclusivity

Law360, Washington (December 7, 2012, 7:30 PM EST) -- Mylan Pharmaceuticals Inc. told a Washington federal judge on Friday that it should be allowed to start marketing a generic version of its hypertension drug valsartan, alleging Ranbaxy Laboratories Ltd. has forfeited its exclusivity rights by not actively pursuing U.S. Food and Drug Administration approval.

Mylan claims Ranbaxy has had years to seek approval for its abbreviated new drug application yet there's no word when it will be ready to gain final FDA approval for the product, and urged U.S. District Judge John D. Bates to...
To view the full article, register now.

Related

Sections

Case Information

Case Title

MYLAN LABORATORIES LIMITED et al v. FOOD AND DRUG ADMINISTRATION et al


Case Number

1:12-cv-01637

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

John D. Bates

Date Filed

October 2, 2012

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.